India covid-19 vaccine symptomatic India

India's COVID vaccine shown 78% effective in phase 3 trial

Reading now: 345
www.cidrap.umn.edu

Interim results from a phase 3 clinical trial of the BBV152 Bharat Biotech COVID-19 vaccine from India show that two doses offer 77.8% efficacy against symptomatic infection, according to a study today in The Lancet.Just last week the World Health Organization (WHO) approved emergency use of the vero cell–derived vaccine in adults.

It is the eighth COVID-19 vaccine to receive WHO emergency use listing.Led by Bharat researchers, the study involved 24,419 participants aged 18 to 97 years at 25 hospitals in India 2 weeks after the second dose of the vaccine from Nov 16, 2020, to May 17, 2021.

At the time, India experienced a peak of more than 400,000 new daily COVID-19 cases, including those caused by the Delta (B1617.2) variant.Participants

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA